M&As this week: Telix Pharmaceuticals, PCI Pharma, DZS Clinical Services

14th September 2018 (Last Updated September 14th, 2018 00:00)

Telix Pharmaceuticals Limited has acquired Atlab Pharma SAS for $10m.

Telix Pharmaceuticals Limited has acquired Atlab Pharma SAS for $10m.

Based in Australia, Telix is a clinical-stage biotechnology company engaged in the development of diagnostic and therapeutic products, while Atlab Pharma is an antibody-targeted anti-cancer drugs developer based in France.

The transaction will enable the acquirer company to expand the indication for Lutetium-labelled huJ591, an anti-prostate specific membrane antigen (PSMA) antibody and a validated target in prostate cancer.

PCI Pharma Services has signed an agreement with Sherpa Clinical Packaging to acquire the latter.

Based in the US, PCI Pharma is a drug development services provider for the global healthcare market, while Sherpa Clinical Packaging, also based in the US, is a provider of clinical trial material management services.

The transaction will enable the acquirer company to bolster its position in the outsourced clinical trial support services in the US. It will also enable PCI to support its customers from initial phases of clinical development to commercial launch.

WDB Medical Data (WDBMD) has completed the acquisition of DZS Clinical Services for an undisclosed sum.

"PCI Pharma Services has signed an agreement with Sherpa Clinical Packaging to acquire the latter."

DZS will become a consolidated group company of the WDB Group, upon completion of the transaction.

Based in the US, DZS Clinical Services is a clinical data and trial management solutions provider, while WDBMD, also based in the US, is a provider of contract research and development services and a subsidiary of WDB Holdings.

The acquisition will enable WDBMD to expand its business and offer a wide range of services to its clients.

Bison Capital Acquisition Corp (BCAC) has signed a definitive merger agreement with Xynomic Pharmaceuticals.

Xynomic will operate as a fully owned subsidiary of BCAC, while BCAC will be renamed as Xynomic Pharmaceuticals Holdings, post the completion of the merger.

Based in China, BCAC operates as a blank check company, while Xynomic Pharmaceuticals, also based in China, is engaged in the development and commercialisation of oncology drug candidates.

The merger is expected to enable Xynomic to develop and commercialise novel oncology drugs for unmet medical needs.